Niall C. Tebbutt
A5080423970- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Metastasis and carcinoma case studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Fibroblast Growth Factor Research
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Gastrointestinal Tumor Research and Treatment
- Cancer Mechanisms and Therapy
- Monoclonal and Polyclonal Antibodies Research
- Melanoma and MAPK Pathways
- Cancer Cells and Metastasis
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
Austin Health
2016-2025
Olivia Newton-John Cancer Wellness & Research Centre
2016-2025
Austin Hospital
2013-2025
The University of Melbourne
2009-2024
La Trobe University
2010-2024
The University of Sydney
2007-2023
Sunshine Coast University Hospital
2023
Heidelberg Repatriation Hospital
2016-2020
Australasian Lung Cancer Trials Group
2009-2020
Melbourne Health
2016-2019
Treatment with cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, improves overall and progression-free survival preserves quality of life in patients colorectal cancer that has not responded to chemotherapy. The mutation status K-ras gene tumor may affect response cetuximab have treatment-independent prognostic value.We analyzed samples, obtained from 394 572 (68.9%) who were randomly assigned receive plus best supportive care or alone, look for...
The AVAGAST study showed that adding bevacizumab to chemotherapy in patients with advanced gastric cancer improves progression-free survival and tumor response rate but not overall survival. To examine the hypothesis angiogenic markers may have predictive value for efficacy cancer, included a prospective, mandatory biomarker program.Patients previously untreated, locally or metastatic were randomly assigned (n = 387) placebo combination chemotherapy. Blood tissue samples collected at...
To evaluate neoadjuvant capecitabine/oxaliplatin before chemoradiotherapy (CRT) and total mesorectal excision (TME) in newly diagnosed patients with magnetic resonance imaging (MRI) -defined poor-risk rectal cancer.MRI criteria for cancer were tumors within 1 mm of fascia (ie, circumferential resection margin threatened), T3 at or below levators, extending > = 5 into perirectal fat, T4 tumors, T1-4N2 tumors. Patients received 12 weeks followed by concomitant capecitabine radiotherapy. TME...
Purpose The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study pretreated advanced gastric cancer. This international, double-blind, III compared and safety with that best supportive care (BSC) previously treated Patients Methods cancer progressed after one or two lines systemic chemotherapy were randomly assigned to 10 mg/d (assignment schedule: 2:1) matching placebo, both given BSC. Randomization was stratified by previous (one v...
To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients metastatic colorectal cancer (mCRC) an open-label, three-arm randomized trial.Overall, 471 Australia, New Zealand, and the United Kingdom previously untreated, unresectable mCRC were randomly assigned following: capecitabine; plus bevacizumab (CB); capecitabine, mitomycin (CBM). We compared CB CBM for (PFS). Secondary end points included overall...
Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival patients who receive adjuvant gemcitabine after resection. Microarrays from 434 randomized to chemotherapy the ESPAC-3 trial (plus controls ESPAC-1/3) were stained with 10D7G2 anti-hENT1 antibody. Patients classified as having high hENT1 expression if mean H score for their cores was above overall median (48). High and low hENT1-expressing groups compared using Kaplan–Meier curves,...
ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases metastatic cancer (mCRC) patients bearing rearrangements who benefited from anti-ALK, ROS, TrkA-B-C therapies have been reported previously. Here we aimed at characterizing the clinical molecular landscape rearranged mCRC.Clinical features characteristics 27 mCRC tumors were compared with those a cohort 319 not by means Fisher's exact, χ2 test, or Mann-Whitney test as appropriate. Overall survival curves...
Local and distant disease recurrence are frequently observed following pancreatic cancer resection, but an improved understanding of resection margin assessment is required to aid tailored therapies.
Abstract Purpose. This analysis pooled individual patient data from randomized controlled trials (RCTs) to more thoroughly examine clinical outcomes when adding bevacizumab chemotherapy for patients with metastatic colorectal cancer (mCRC). Patients and Methods. Patient were the first-line AVF2107, NO16966, ARTIST, AVF0780, AVF2192, AGITG MAX RCTs second-line E3200 RCT. All analyses based on intent-to-treat population. To assess differences in time-to-event variables by treatment...
Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods conducted international (Australia New Zealand, South Korea, Canada) randomized phase II trial which patients were randomly assigned at a two-to-one ratio stratified by lines prior chemotherapy for disease (one v two) region. Eligible received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 each 28-day cycle until...
<h3>Importance</h3> Biliary tract cancers represent a rare group of malignant conditions with very limited treatment options. Patients advanced disease have poor outcome current therapies. <h3>Objective</h3> To evaluate the efficacy and safety combination immunotherapy nivolumab ipilimumab in patients biliary cancers. <h3>Design, Setting, Participants</h3> The CA209-538 prospective multicenter phase 2 nonrandomized clinical trial included including This subgroup analysis evaluated 39 from...
In patients with resectable colorectal liver metastases (CRLM), the role of pre- and postoperative systemic therapy continues to be debated. Previous studies have shown that circulating tumor DNA (ctDNA) analysis, as a marker minimal residual disease, is powerful prognostic factor in nonmetastatic cancer (CRC). Serial analysis ctDNA CRLM could inform optimal use perioperative chemotherapy. Here, we performed validation study confirm impact observed previous discovery study.We prospectively...
This randomized, open-label trial compared the efficacy and safety of adjuvant
An array of cell-surface antigens expressed by human cancers have been identified as targets for antibody-based therapies. The great majority these antibodies do not specificity cancer but recognize on a range normal cell types (differentiation antigens). Over the past two decades, our group has analyzed thousands mouse monoclonal and battery with limited representation cells. most tumor-specific is 806, an antibody that detects unique epitope epidermal growth factor receptor (EGFR) exposed...